[{"orgOrder":0,"company":"BDD Pharma","sponsor":"Cingulate Therapeutics, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buspirone Hydrochloride","moa":"5-HTA receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BDD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDD Pharma \/ BDD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"BDD Pharma \/ BDD Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by BDD Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : CTx-2103 (Buspirone Hydrochloride) is a novel, trimodal, extended-release tablet of buspirone incorporating Cingulate’s proprietary PTR™ drug delivery platform, and is being studied for the treatment of anxiety and/or anxiety-related disorders.

                          Brand Name : CTx-2103

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 24, 2022

                          Lead Product(s) : Buspirone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Recipient : Cingulate Therapeutics, LLC

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank